Lataa...
Evaluation of a reductively activated duocarmycin prodrug against murine and human solid cancers
In treating cancer with clinically approved chemotherapies, the high systemic toxicity and lack of selectivity for malignant cells often result in an overall poor response rate. One pharmacological approach to improve patient response is to design targeted therapies that exploit the cancer milieu by...
Tallennettuna:
| Päätekijät: | , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Landes Bioscience
2013
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3813569/ https://ncbi.nlm.nih.gov/pubmed/23760495 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.24348 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|